MolecuLight Inc., a pioneering medical device company focused on fluorescence imaging for wound care, has announced that it has secured a $27.5 million investment from Hayfin Capital Management LLP (Hayfin). This funding will help accelerate the company’s growth in key markets, including the United States, Canada, and Europe, with plans to expand its presence across hospital in-patient and out-patient clinics, independent wound care clinics, podiatric care, mobile services, skilled nursing facilities, and long-term care centres.
MolecuLight’s technology, which offers point-of-care fluorescence imaging, enables healthcare providers to detect harmful bacteria in wounds in real-time. This innovation is transforming the way infections are identified and managed, improving patient outcomes while reducing healthcare costs. By visualising bacterial load in wounds, MolecuLight’s devices allow clinicians to make informed decisions on treatment, helping to shorten healing times, reduce unnecessary antibiotic usage, and avoid complications, all while minimising the risk of skin substitute product failure.
Anil Amlani, CEO of MolecuLight, expressed his excitement about the new partnership with Hayfin, a global alternative investment manager with a strong track record in wound care investments. “This investment will allow us to further accelerate our efforts to improve how wounds are treated worldwide,” Amlani said. “We will expand our footprint to reach more healthcare providers and patients, while continuing to innovate with new features such as thermal imaging, 3D wound visualisation, and other advancements, which we plan to announce over the next six months.”
The investment from Hayfin will provide MolecuLight with the capital needed to scale its operations, enhance its research and development, and expand its product offerings. Andrew Merrill, Managing Director of Hayfin, highlighted the transformative potential of MolecuLight’s technology. “MolecuLight’s imaging device is a best-in-class product with significant market traction, and the company has a strong research and development pipeline. These factors make it an ideal fit for our investment strategy. We are excited to support MolecuLight’s growth, which will have a positive impact on patients, healthcare providers, and the healthcare system as a whole,” Merrill stated.
MolecuLight’s fluorescence imaging devices are already being used in a variety of clinical settings, helping healthcare providers to better detect infections and make more effective treatment decisions. With the new funding, the company aims to reach even more healthcare facilities and expand its impact across the wound care space.
The investment comes at a critical time as the demand for advanced wound care solutions continues to grow, driven by an ageing population and increasing prevalence of chronic conditions such as diabetes. MolecuLight’s innovative approach positions it at the forefront of the wound care industry, offering clinicians an effective and efficient tool to improve patient care.
As the company looks to the future, MolecuLight is set to continue its mission to revolutionise wound care and improve patient outcomes on a global scale. With the backing of Hayfin, the company is well-positioned to take its technology to new heights and broaden its impact across the healthcare landscape.